Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab (QL1706) vs Sintilimab in Advanced ICC
NCT07152769Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2025
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in intrahepatic cholangiocarcinoma (ICC), sponsored by Fudan University. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07152769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07152769.